

ANTI-TNF MONITORING EXPERIENCE IN A 3RD LEVEL HOSPITAL IN LATIN AMERICA

Monica Contreras

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A prospective study of 58 pediatric IBD patients in Argentina found that therapeutic drug monitoring of infliximab revealed pharmacokinetic failure in 75.8% of maintenance patients with loss of response, while BMI below 18.5 and very early onset IBD were associated with suboptimal drug levels.

KEY POINTS

- Among 58 pediatric IBD patients, 67 infliximab level measurements were performed during induction (25 determinations) and maintenance (42 determinations) phases at a high-complexity hospital in Latin America from July 2022 to February 2023.
- Median infliximab levels were 14 ug/ml during induction and 4 ug/ml during maintenance, with median anti-drug antibody levels of 1 AU/ml and 98 AU/ml respectively.
- Patients with BMI below 18.5 had suboptimal drug levels compared to those with normal BMI, and very early onset IBD patients had significantly lower optimal levels than non-VEOIBD patients.
- Loss of response occurred in 64.4% of maintenance patients, with 75.8% attributed to pharmacokinetic failure and 24.1% to pharmacodynamic failure; 31.8% of pharmacokinetic failures also showed immunological mechanisms.
- The authors note that therapeutic monitoring data are limited in Latin America where empirical optimization is widely used, and target levels for different phenotypes and treatment phases remain unclear especially in pediatrics.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/95b3906c-743c-11ee-97fc-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.